{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:52:19Z","timestamp":1791305539730,"version":"4.3.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Drug-resistant tuberculosis (TB) hinders global TB control. Rifampicin-resistant TB (RR-TB) prevalence, in C\u00f4te d\u2019Ivoire, was 4.6% (95% confidence interval [95% CI]: 2.4\u20136.7) for new cases and 22% (95% CI: 13.7\u201330.3) with retreatment cases in 2016. The TB drug resistance survey (DRS) conducted in 2023 aimed to determine the updated prevalence of resistance among new, previously treated TB cases and to characterize the genotypes of circulating\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      strains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A nationwide, cluster-based cross-sectional DRS was conducted in a 6-month timeframe in 44 health facilities across the country, grouped into 45 clusters according to the World Health Organization guidance. Bacteriologically confirmed pulmonary TB cases were recruited after giving informed consent. Xpert\n                      <jats:sup>\u00ae<\/jats:sup>\n                      MTB\/RIF Ultra, Hain MTBDR\n                      <jats:italic toggle=\"yes\">plus<\/jats:italic>\n                      and MTBDR\n                      <jats:italic toggle=\"yes\">sl<\/jats:italic>\n                      were carried out on sputum samples. All samples with resistance detected and 10% of rifampicin (RIF) susceptible TB cases were cultured in liquid medium with\n                      <jats:italic toggle=\"yes\">Mycobacterium<\/jats:italic>\n                      growth incubator tube (MGIT) (MGIT 960). Phenotypic drug susceptibility testing was performed for isoniazid (INH), RIF, amikacin (AMK), moxifloxacin, levofloxacin, clofazimine, bedaquiline, and linezolid. Whole-genome or targeted next-generation sequencing was conducted on 120 selected drug-resistant and susceptible strains. KoboCollect v2013.1.2 was used for data collection and storage. For statistical and cluster analysis, STATA 19.5 and core genome multilocus sequence typing in Ridom SeqSphere + were used, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>1024 participants were enrolled, 947 (92.5%) were new cases. INH monoresistant TB prevalence was 4.8% (95% CI: 3.6\u20136.4) in new cases and 5.6% (95% CI: 1.5\u201318.8) in retreatment cases. Multidrug-resistant TB (MDR-TB) prevalence was 2.5% (95% CI: 1.7%\u20133.8%) in new and 14.1% (95% CI: 7.0%\u201326.5%) in previous treated cases. Among RR-TB, MDR-TB prevalence was 89.5% (95% CI: 73.8\u201396.3), of whom 2 pre-extensively drug-resistant (XDR) TB and 1 XDR-TB were detected. Sequencing revealed a predominant circulation of lineage 4.6.2.2 and 4.1 (28% each) following by lineage 6 (11%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Progress has been made in combating TB drug resistance in C\u00f4te d\u2019Ivoire compared to the previous DRS. Molecular tools have permitted to detect heteroresistance or mixed infection and the existence of circulating virulent strains associated with alarming rates of drug resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_92_26","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:00:10Z","timestamp":1790823610000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Fourth National Anti-Tuberculosis Drug Resistance Survey in C\u00f4te d\u2019Ivoire Incorporating Sequencing"],"prefix":"10.4103","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7062-4191","authenticated-orcid":false,"given":"Kouassi Raymond","family":"N\u2019GUESSAN","sequence":"first","affiliation":[{"name":"Mycobacteria Unit, National Tuberculosis Reference Laboratory, Department of Bacteriology-Virology, Abidjan, C\u00f4te d\u2019Ivoire, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Annabelle","family":"BAI ORSOT BOSSO","sequence":"additional","affiliation":[{"name":"Mycobacteria Unit, National Tuberculosis Reference Laboratory, Department of Bacteriology-Virology, Abidjan, C\u00f4te d\u2019Ivoire, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naminata","family":"KARAMOKO BAMBA","sequence":"additional","affiliation":[{"name":"Mycobacteria Unit, National Tuberculosis Reference Laboratory, Department of Bacteriology-Virology, Abidjan, C\u00f4te d\u2019Ivoire, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel Blaise","family":"TIOPSOP TSATSOP","sequence":"additional","affiliation":[{"name":"National School of Statistics and Applied Economics, Abidjan, C\u00f4te d\u2019Ivoire, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ADADE","family":"Kouakou Olivier","sequence":"additional","affiliation":[{"name":"National TB Control Program, Abidjan, C\u00f4te d\u2019Ivoire, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ADAGRA","family":"Guy Damien","sequence":"additional","affiliation":[{"name":"National TB Control Program, Abidjan, C\u00f4te d\u2019Ivoire, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EDDYANI","family":"Miriam","sequence":"additional","affiliation":[{"name":"Independent Consultant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SALUZZO","family":"Francesca","sequence":"additional","affiliation":[{"name":"Emerging Bacterial Pathogens Unit, TB Supranational Reference Laboratory, IRCCS San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CABIBBE","family":"Andrea Maurizio","sequence":"additional","affiliation":[{"name":"Emerging Bacterial Pathogens Unit, TB Supranational Reference Laboratory, IRCCS San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CIRILLO","family":"Daniela Maria","sequence":"additional","affiliation":[{"name":"Emerging Bacterial Pathogens Unit, TB Supranational Reference Laboratory, IRCCS San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KOUAKOU","family":"Kouakou Jacquemin","sequence":"additional","affiliation":[{"name":"Independent Consultant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"R1-20261006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"R3-20261006","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3201\/eid2809.220458","article-title":"Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006\u20132019","volume":"28","author":"Kherabi","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"R7-20261006","first-page":"805","article-title":"Primary resistance to antituberculosis drugs: A national survey conducted in C\u00f4te d\u2019Ivoire in 1995-1996","volume":"3","author":"Dosso","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-20261006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1556\/1886.2018.00001","article-title":"Multidrug-resistant tuberculosis in C\u00f4te d\u2019Ivoire from 1995 to 2016: Results of national surveys","volume":"8","author":"N\u2019Guessan","year":"2018","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"R9-20261006","first-page":"1453","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"BMJ"},{"key":"R11-20261006","doi-asserted-by":"crossref","first-page":"ofaf367","DOI":"10.1093\/ofid\/ofaf367","article-title":"The Ethiopian third national tuberculosis drug resistance survey incorporating whole genome sequencing","volume":"12","author":"Moga","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"R13-20261006","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4103\/ijmy.ijmy_162_24","article-title":"Prevalence and temporal trends of multidrug-resistant tuberculosis in Iran from 1981 to 2023: A systematic review and meta-analysis","volume":"13","author":"Ayoubi","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"R14-20261006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/ijmy.ijmy_101_23","article-title":"Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible Mycobacterium tuberculosis clinical isolates","volume":"12","author":"Hasan","year":"2023","journal-title":"Int J Mycobacteriol"},{"issue":"3","key":"R15-20261006","doi-asserted-by":"crossref","first-page":"e01671","DOI":"10.1128\/aac.01671-24","article-title":"Xpert MTB\/RIF Ultra-resistant and MTBDR plus-susceptible rifampicin results in people with tuberculosis: Utility of FluoroType MTBDR and deep sequencing","volume":"69","author":"Ghebrekristos","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20261006","doi-asserted-by":"crossref","first-page":"105142","DOI":"10.1016\/j.meegid.2021.105142","article-title":"Discordant results between genotypic and phenotypic assays (Xpert MTB\/RIF versus BACTEC MGIT 960 system) for detection of RIF-resistant Mycobacterium tuberculosis isolates in a high burden region","volume":"96","author":"Rafael","year":"2021","journal-title":"Infect Genet Evol"},{"key":"R17-20261006","doi-asserted-by":"crossref","first-page":"dlab101","DOI":"10.1093\/jacamr\/dlab101","article-title":"False detection of rifampicin resistance using Xpert(\u00ae) MTB\/RIF ultra assay due to an A451V mutation in Mycobacterium tuberculosis","volume":"3","author":"Fitzgibbon","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"R18-20261006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/ijmy.ijmy_176_22","article-title":"Line probe assay test in new cases of tuberculosis with rifampicin resistance not detected by Xpert MTB\/RIF","volume":"11","author":"Soedarsono","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R19-20261006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02175-18","article-title":"Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis.","volume":"63","author":"Gygli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20261006","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1038\/s41598-025-86079-8","article-title":"Global epidemiology of Mycobacterium tuberculosis lineage 4 insights from Ecuadorian genomic data","volume":"15","author":"Morey-Le\u00f3n","year":"2025","journal-title":"Sci Rep"},{"key":"R22-20261006","doi-asserted-by":"crossref","first-page":"108696","DOI":"10.1016\/j.ijid.2026.108696","article-title":"Geographical distribution of Mycobacterium tuberculosis complex lineages in sub-Saharan Africa: An interactive review","volume":"168","author":"Badiane","year":"2026","journal-title":"Int J Infect Dis"},{"key":"R23-20261006","doi-asserted-by":"crossref","first-page":"e0011619","DOI":"10.1371\/journal.pntd.0011619","article-title":"Mycobacterium tuberculosis complex drug-resistance, phylogenetics, and evolution in Nigeria: Comparison with Ghana and Cameroon","volume":"17","author":"Sahal","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"R24-20261006","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s12866-025-04430-5","article-title":"Molecular epidemiology of tuberculosis in Western Burkina Faso: Insights from a MIRU-VNTR study","volume":"25","author":"Nagalo","year":"2025","journal-title":"BMC Microbiol"},{"key":"R25-20261006","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fmed.2020.00161","article-title":"Whole genome sequencing and spatial analysis identifies recent tuberculosis transmission hotspots in Ghana","volume":"7","author":"Asare","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R26-20261006","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.ijregi.2024.100501","article-title":"Clinical epidemiology, genetic diversity, and drug susceptibility patterns by whole genome sequencing of Mycobacterium tuberculosis complex isolates in Gabon from 2012 to 2022","volume":"14","author":"Adegbite","year":"2025","journal-title":"IJID Reg"},{"key":"R27-20261006","doi-asserted-by":"crossref","first-page":"RP99062","DOI":"10.7554\/eLife.99062.4","article-title":"Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages","volume":"13","author":"Arbu\u00e9s","year":"2025","journal-title":"Elife"},{"issue":"2","key":"R28-20261006","first-page":"000477","article-title":"Phylogenomics of Mycobacterium africanum reveals a new lineage and a complex evolutionary history","volume":"7","author":"Coscolla","year":"2021","journal-title":"Microb Genom"},{"key":"R29-20261006","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1038\/s41598-026-42003-2","article-title":"Genome-wide analyses of Mycobacterium tuberculosis complex isolates reveal insights into circulating lineages and drug resistance mutations in The Gambia","volume":"16","author":"Faal","year":"2026","journal-title":"Sci Rep"},{"key":"R30-20261006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4103\/ijmy.ijmy_195_22","article-title":"Evaluation of xpert Mycobacterium tuberculosis rifampicin for tuberculosis diagnosis in a reference laboratory","volume":"11","author":"Ule Belotti","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R31-20261006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/ijmy.ijmy_70_22","article-title":"Diagnostic utility of GenoType MTBDRsl assay for the detection of moxifloxacin-resistant Mycobacterium tuberculosis, as compared to phenotypic method and whole-genome sequencing","volume":"11","author":"Yadav","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R32-20261006","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4103\/ijmy.ijmy_202_23","article-title":"Diagnostic accuracy of FluoroCycler XT MTBDR assay for detection of rifampicin and isoniazid-resistant Mycobacteria tuberculosis in clinical isolates from Kenya","volume":"13","author":"Mwangi","year":"2024","journal-title":"Int J Mycobacteriol"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_92_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:02:47Z","timestamp":1791302567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_92_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_92_26","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}